MX355063B - Calcimiméticos y métodos para su uso. - Google Patents

Calcimiméticos y métodos para su uso.

Info

Publication number
MX355063B
MX355063B MX2014005662A MX2014005662A MX355063B MX 355063 B MX355063 B MX 355063B MX 2014005662 A MX2014005662 A MX 2014005662A MX 2014005662 A MX2014005662 A MX 2014005662A MX 355063 B MX355063 B MX 355063B
Authority
MX
Mexico
Prior art keywords
methods
calcimimetics
effective
levels
kidney disease
Prior art date
Application number
MX2014005662A
Other languages
English (en)
Other versions
MX2014005662A (es
Inventor
Walter Sarah
Bell Gregory
E Tomlinson James
Original Assignee
Kai Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47258113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX355063(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kai Pharmaceuticals Inc filed Critical Kai Pharmaceuticals Inc
Publication of MX2014005662A publication Critical patent/MX2014005662A/es
Publication of MX355063B publication Critical patent/MX355063B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a métodos para tratar sujetos que sufren de nefropatía crónica-trastorno óseo y mineral u otros trastornos que son el resultado de hiperparatiroidismo primario o secundario. Los métodos son efectivos en la reducción de los niveles séricos de la hormona paratiroidea (PTH) y de los niveles séricos de calcio en pacientes que se someten a hemodiálisis. Los métodos descritos en la presente también son efectivos en la desaceleración del avance de la nefropatía y en preservar la función renal. Se proporcionan también, composiciones usadas en los métodos descritos y comprenden calcimiméticos, que funcionan como agonistas del receptor sensible al calcio (CaSR).
MX2014005662A 2011-11-10 2012-11-12 Calcimiméticos y métodos para su uso. MX355063B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558389P 2011-11-10 2011-11-10
PCT/US2012/064717 WO2013071262A1 (en) 2011-11-10 2012-11-12 Calcimimetics and methods for their use

Publications (2)

Publication Number Publication Date
MX2014005662A MX2014005662A (es) 2014-11-10
MX355063B true MX355063B (es) 2018-04-04

Family

ID=47258113

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005662A MX355063B (es) 2011-11-10 2012-11-12 Calcimiméticos y métodos para su uso.

Country Status (9)

Country Link
US (3) US20140315809A1 (es)
EP (1) EP2776129B2 (es)
JP (2) JP6204369B2 (es)
CN (2) CN104168955A (es)
AU (1) AU2012335009B2 (es)
CA (1) CA2854911C (es)
HK (1) HK1202086A1 (es)
MX (1) MX355063B (es)
WO (1) WO2013071262A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2348114T3 (en) 2004-04-21 2018-09-03 Alexion Pharma Inc BONE DELIVERY CONJUGATES AND PROCEDURE TO USE IT FOR TARGETING PROTEINS AGAINST BONE
MX2012001213A (es) 2009-07-29 2012-06-12 Kai Pharmaceuticals Inc Agentes terapeuticos para reducir los niveles de la hormona paratiroidea.
CN114376970A (zh) * 2013-06-28 2022-04-22 美国安进公司 Etelcalcetide (AMG 416)的稳定的液体制剂
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
EP3222278B1 (en) * 2014-10-24 2023-06-14 Launx Biomedical Co., Ltd. Use of azelnidipine in preparing medicinal composition for treating cancers
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
JP6868561B2 (ja) * 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
MX2018002121A (es) 2015-08-17 2018-06-18 Alexion Pharma Inc Elaboracion de fosfatasas alcalinas.
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
CN106928320B (zh) * 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. METHODS OF TREATING HYPOPHOSPHATASE IN CHILDREN
WO2017173413A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3464573A4 (en) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. IMPACT OF METAL ON THE PRODUCTION OF ALKALINE PHOSPHATASES
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
CN110719786A (zh) 2017-03-31 2020-01-21 阿雷克森制药公司 用于治疗成人和青少年的低磷酸酯酶症(hpp)的方法
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
WO2020081800A1 (en) * 2018-10-18 2020-04-23 Fresenius Medical Care Holdings, Inc. Techniques for modeling parathyroid gland functionality and calcimimetic drug activity
MX2022006892A (es) * 2019-12-09 2022-10-07 Beijing Tuo Jie Biopharmaceutical Co Ltd Compuesto agonista del receptor sensor de calcio y aplicación del mismo.
CN115087662B (zh) * 2020-09-10 2023-09-26 陕西麦科奥特科技有限公司 双特异性融合多肽化合物
CN117500820A (zh) * 2021-06-08 2024-02-02 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用
WO2022257958A1 (zh) * 2021-06-08 2022-12-15 北京拓界生物医药科技有限公司 一种钙敏感受体激动剂的组合物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
WO1998004591A1 (en) * 1996-07-31 1998-02-05 The General Hospital Corporation Novel parathyroid hormone-related peptide analogs
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
EP2070911A2 (en) 2000-07-18 2009-06-17 Bone Care International, Inc. Stabilized 1Alpha-Hydroxy vitamin D
WO2003013543A1 (en) * 2001-08-08 2003-02-20 Genomed, Llc Treatment or prevention of acute renal failure
AU2006227429A1 (en) * 2005-03-17 2006-09-28 Amgen Inc. Methods of decreasing calcification
CN103961686A (zh) 2006-11-16 2014-08-06 凯制药公司 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽
WO2008122010A1 (en) * 2007-04-02 2008-10-09 Concert Pharmaceuticals, Inc. Pharmaceutical calcimimetics
MX2012001213A (es) * 2009-07-29 2012-06-12 Kai Pharmaceuticals Inc Agentes terapeuticos para reducir los niveles de la hormona paratiroidea.
GB0913525D0 (en) * 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method

Also Published As

Publication number Publication date
MX2014005662A (es) 2014-11-10
AU2012335009A1 (en) 2014-05-29
EP2776129B2 (en) 2020-06-17
JP6204369B2 (ja) 2017-09-27
JP2015502346A (ja) 2015-01-22
EP2776129A1 (en) 2014-09-17
EP2776129B1 (en) 2017-03-29
CN104168955A (zh) 2014-11-26
US20170252397A1 (en) 2017-09-07
HK1202086A1 (en) 2015-09-18
CA2854911C (en) 2019-09-24
CN109985228A (zh) 2019-07-09
US20160175383A1 (en) 2016-06-23
US20140315809A1 (en) 2014-10-23
CA2854911A1 (en) 2013-05-16
AU2012335009B2 (en) 2017-08-31
WO2013071262A1 (en) 2013-05-16
JP2017160269A (ja) 2017-09-14

Similar Documents

Publication Publication Date Title
MX355063B (es) Calcimiméticos y métodos para su uso.
BR112015009948A2 (pt) antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios
MX2018006477A (es) Anticuerpos y metodos de uso de estos.
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
EA201692001A1 (ru) Способ получения amg 416
PH12015502275B1 (en) Therapuetic uses of empagliflozin
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
EA201270803A1 (ru) Тиоацетатные соединения, композиции на их основе и способы их применения
CO6791571A2 (es) Moduladores de la proteína tirosina quinasa 7 (ptk7) para el tratamiento diagnóstico o profilaxis de trastornos neoplásicos
MX365835B (es) Uso de akkermansia para tratar trastornos metabolicos.
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
PH12018502593A1 (en) Combinations of linagliptin and metformin
EA201792465A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201400119A1 (ru) Фармацевтическая композиция, способы лечения и их применение
EA201270767A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов
EA201391581A1 (ru) Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств
WO2014015157A3 (en) Sigma receptor ligands for modulating cellular protein homeostasis
MX2015013939A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
EP4285993A3 (en) Growth differentiation factor 15 as biomarker for metformin
NI201600021A (es) Inhibidores de rorc2 heterobicicloarilo y sus métodos de uso
IN2014CN04014A (es)

Legal Events

Date Code Title Description
FG Grant or registration